Colon and Rectal Cancers Clinical Trials Planning Meeting Executive Summary

Meeting dates: January 7-8, 2011

Prepared by meeting co-Chairs and NCI Staff

Colon: Neal J. Meropol, M.D., Axel Grothey, M.D.

Rectal: Elin Sigurdson, M.D., Ph.D., Bruce Minsky, M.D.

NCI: Deborah Jaffee, Ph.D., Jack Welch, M.D.

The NCI Gastrointestinal Cancer Steering Committee Colon and Rectal Task Forces held a Clinical Trials Planning Meeting (CTPM) in Bethesda, MD on January 7-8, 2011. The overall goal of the meeting was to develop a blueprint for the next generation of clinical trials for patients with colorectal cancer. The meeting included 103 invited guests, representing NCI and extramural participation, with expertise in colorectal cancer patient management, clinical trials, biostatistics, translational science, and patient advocacy. The meeting included separate agendas for colon cancer and rectal cancer participants, with conjoint sessions as appropriate. Interaction between meeting participants was fostered through small group breakout sessions, and discussion following more formal scheduled presentations.

This Executive Summary presents the consensus arising from the CTPM. It is organized by disease site. These recommendations are not meant to address all clinical contexts, but rather represent priorities for publicly-funded clinical research.

General

- Advances in understanding molecular characterization of tumors and germline variation requires a national infrastructure to provide real-time clinical testing of patient specimens for treatment assignment.
- Integral marker studies are a high priority.
- Existing tissue banks should be exploited for predictive classifier discovery; treatment-classifier-response relationships defined in banked tissue are necessary to design prospective validation studies.
- Banking of patient tumors and germline DNA for future research is an imperative.
- High-priority therapeutic targets include signaling kinases, stem cells, DNA damage response, host response.

Colon Cancer

Early Stage Adjuvant Therapy

- There is not currently a new agent of sufficient promise to warrant testing in a phase III adjuvant study.
- A triple drug combination regimen, FOLFOXIRI should be tested against standard FOLFOX as adjuvant therapy in high-risk stage III colon cancers.
- Neoadjuvant approaches in early stage colon cancer should be considered to establish a model for evaluation of agents potentially active in the adjuvant setting.
- Discovery efforts should continue to focus on identification of populations at particularly high risk of recurrence, as a setting for testing new agents in early stage disease.

Resectable liver-confined metastatic disease
• Preoperative treatment with a new agent will permit in vivo pharmacodynamic assessment of treatment effect.
• “Adjuvant” treatment after potentially curative resection will allow testing of new approaches in this high-risk setting using resected stage IV disease as a model for micrometastatic disease.

Oligometatatic disease with extrahepatic component
• A common clinical setting is liver metastasis with intraabdominal extrahepatic disease. A study is suggested to test the combination of surgical (resection/ablation) plus systemic approach in the setting where minimal residual disease can be accomplished with surgical treatment.

Unresectable metastatic disease
• Tumors with BRAF mutations have a poor prognosis. A first-line randomized phase II study involving new agents, with or without conventional cytotoxics is suggested in this population.
• Patients often have a period of stable disease after initial treatment response. This “window” after response is an opportunity to test targeted approaches in molecularly-defined patient groups. A randomized phase II study of combinations of signaling inhibitors is suggested.
• Irinotecan is commonly administered as a component of second-line treatment. A phase II trial of irinotecan plus novel agent(s) with treatment assignment based on tumor molecular characterization is suggested.
• “Last-line”, salvage settings present a patient population of high clinical need with opportunities for drug development.

Rectal Cancer
• Current treatment algorithms typically involve trimodality therapy in a “one-size fits all” approach. Future trials should tailor treatment to patient risk of local and distant recurrence.
• For upper rectal cancer, studies should explore the selective use of radiotherapy.
• For lower rectal cancer or upper rectal cancer at high risk for local recurrence, studies should explore novel agents in addition to a backbone of neoadjuvant fluoropyrimidine plus radiation.
• Explore the role of 5 x 5 radiation therapy in high risk rectal cancer.
• Examine/identify appropriate early end-points/prognostic markers for neoadjuvant clinical trials that can subsequently be integrated into future trials. These endpoints and classifiers will correlate with local recurrence and overall, and include pathological assessment, imaging biomarkers, and molecular classifiers.
NCI Colon/Rectal Cancer Clinical Trials Planning Meeting Attendees
January 7-8, 2011
Bethesda, Maryland

Steven Alberts, M.D.
Mayo Clinic
alberts.steven@mayo.edu

Carmen Allegra, M.D.
University of Florida
carmen.allegra@medicine.ufl.edu

Michael Anderson, M.A.
The EMMES Corporation
manderson@emmes.com

Dirk Arnold, M.D.
University Medical Center Hamburg-Eppendorf
d.arnold@uke.de

Jonathan Ashman, M.D.
Mayo Clinic
ashman.jonathan@mayo.edu

Nancy Baxter, M.D.
St. Michael’s Hospital
baxtern@smh.ca

Jacqueline Benedetti, Ph.D.
Fred Hutchinson Cancer Research Center
jbenedet@fhcrc.org

Al B. Benson, III, M.D.
Northwestern University
a-benson@northwestern.edu

Adam Berger, M.D.
Thomas Jefferson University
adam.berger@jefferson.edu

A. William Blackstock, M.D.
Wake Forest University
ablackst@wfubmc.edu

Charles Blanke, M.D.
University of British Columbia
cblanke@bccancer.bc.ca

Bruce Boman, M.D.
Christiana Care Health System
brboman@christianacare.org

Gina Brown, M.D.
Royal Marsden Hospital
gina.brown@rmh.nhs.uk

Sandra Casak, M.D.
Food and Drug Administration
sandra.casack@fda.hhs.gov

Paul Catalano, Sc.D.
Dana-Farber Cancer Institute
pcata@jimmy.harvard.edu

George Chang, M.D.
University of Texas M.D. Anderson Cancer Center
gchang@mdanderson.org

Michael Choti, M.D., M.B.A.
Johns Hopkins University
mchoti@jhmi.edu

Christopher Crane, M.D.
University of Texas M.D. Anderson Cancer Center
ccrane@mdanderson.org

David Cunningham, M.D.
Royal Marsden Hospital
david.cunningham@rmh.nhs.uk

Janine Davies, M.D.
University of North Carolina
daviesj@med.unc.edu

Angela DeMichele, M.D., M.S.C.E.
University of Pennsylvania
angela.demichele@uphs.upenn.edu

Suzanne Demko, M.D.
Food and Drug Administration
suzanne.demko@fda.hhs.gov

Ivan Ding, M.D., M.D.
NCI Translational Research Program
dingi@mail.nih.gov

Daniel Dohan, Ph.D.
University of California, San Francisco
daniel.dohan@ucsf.edu
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Lemery, M.D., M.H.S.</td>
<td>Food and Drug Administration</td>
<td><a href="mailto:steven.lemery@fda.hhs.gov">steven.lemery@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Heinz-Josef Lenz, M.D.</td>
<td>University of Southern California</td>
<td><a href="mailto:lenz@usc.edu">lenz@usc.edu</a></td>
</tr>
<tr>
<td>Jean Lynn, R.N., M.P.H.</td>
<td>NCI Coordinating Center for Clinical Trials</td>
<td><a href="mailto:lynnje@mail.nih.gov">lynnje@mail.nih.gov</a></td>
</tr>
<tr>
<td>Najjia Mahmoud, M.D.</td>
<td>University of Pennsylvania</td>
<td><a href="mailto:najjia.mahmoud@uphs.upenn.edu">najjia.mahmoud@uphs.upenn.edu</a></td>
</tr>
<tr>
<td>Pam McAllister</td>
<td>University of Wisconsin</td>
<td><a href="mailto:pkmcallister@wisc.edu">pkmcallister@wisc.edu</a></td>
</tr>
<tr>
<td>Howard McLeod, Pharm.D.</td>
<td>University of North Carolina</td>
<td><a href="mailto:hmcleod@unc.edu">hmcleod@unc.edu</a></td>
</tr>
<tr>
<td>Neal Meropol, M.D.</td>
<td>University Hospitals Case Medical Center</td>
<td><a href="mailto:neal.meropol@case.edu">neal.meropol@case.edu</a></td>
</tr>
<tr>
<td>Wells Messersmith, M.D.</td>
<td>University of Colorado, Denver</td>
<td><a href="mailto:wells.messersmith@ucdenver.edu">wells.messersmith@ucdenver.edu</a></td>
</tr>
<tr>
<td>Lucio Miele, M.D., Ph.D.</td>
<td>University of Mississippi Cancer Institute</td>
<td><a href="mailto:lmiele@umc.edu">lmiele@umc.edu</a></td>
</tr>
<tr>
<td>Lori Miniasian, M.D.</td>
<td>NCI Community Oncology and Prevention Trials</td>
<td><a href="mailto:minasilo@mail.nih.gov">minasilo@mail.nih.gov</a></td>
</tr>
<tr>
<td>Bruce Minsky, M.D.</td>
<td>University of Chicago</td>
<td><a href="mailto:bruce.minsky@uchospitals.edu">bruce.minsky@uchospitals.edu</a></td>
</tr>
<tr>
<td>Mohammed Mohiuddin, M.D.</td>
<td>Geisinger Cancer Institute</td>
<td><a href="mailto:asemuddin@gmail.com">asemuddin@gmail.com</a></td>
</tr>
<tr>
<td>Margaret Mooney, M.D.</td>
<td>NCI Cancer Therapy Evaluation Program</td>
<td><a href="mailto:mooneym@ctep.nci.nih.gov">mooneym@ctep.nci.nih.gov</a></td>
</tr>
<tr>
<td>Kate Murphy</td>
<td>Colorectal Cancer Coalition</td>
<td><a href="mailto:kate.murphy@fightcolorectalcancer.org">kate.murphy@fightcolorectalcancer.org</a></td>
</tr>
<tr>
<td>Heidi Nelson, M.D.</td>
<td>Mayo Clinic</td>
<td><a href="mailto:nelson.heidi@mayo.edu">nelson.heidi@mayo.edu</a></td>
</tr>
<tr>
<td>Kimmie Ng, M.D., M.P.H.</td>
<td>Dana-Farber Cancer Institute</td>
<td><a href="mailto:kimmie_ng@dfci.harvard.edu">kimmie_ng@dfci.harvard.edu</a></td>
</tr>
<tr>
<td>Michael O’Connell, M.D.</td>
<td>National Surgical Adjuvant Breast and Bowel Project</td>
<td>michael.o’<a href="mailto:connell@nsabp.org">connell@nsabp.org</a></td>
</tr>
<tr>
<td>Peter O’Dwyer, M.D.</td>
<td>University of Pennsylvania</td>
<td>peter.o’<a href="mailto:dwyer@uphs.upenn.edu">dwyer@uphs.upenn.edu</a></td>
</tr>
<tr>
<td>Nicholas Petrelli, M.D.</td>
<td>Christiana Care Health System</td>
<td><a href="mailto:npetrelli@christianacare.org">npetrelli@christianacare.org</a></td>
</tr>
<tr>
<td>Raymond Petryshyn, Ph.D.</td>
<td>NCI Coordinating Center for Clinical Trials</td>
<td><a href="mailto:petryshr@mail.nih.gov">petryshr@mail.nih.gov</a></td>
</tr>
<tr>
<td>Mitchell Posner, M.D.</td>
<td>University of Chicago</td>
<td><a href="mailto:mposner@surgery.bsd.uchicago.edu">mposner@surgery.bsd.uchicago.edu</a></td>
</tr>
<tr>
<td>Cornelis Punt, M.D., Ph.D.</td>
<td>Radboud University Nijmegen Medical Center</td>
<td><a href="mailto:c.punt@onco.umcn.nl">c.punt@onco.umcn.nl</a></td>
</tr>
<tr>
<td>Claus Rödel, M.D.</td>
<td>Johann Wolfgang Goethe-University Frankfurt</td>
<td><a href="mailto:claus.roedel@kgu.de">claus.roedel@kgu.de</a></td>
</tr>
<tr>
<td>Miguel Rodríguez-Bigas, M.D.</td>
<td>University of Texas M.D. Anderson Cancer Center</td>
<td><a href="mailto:mrodbig@mdanderson.org">mrodbig@mdanderson.org</a></td>
</tr>
</tbody>
</table>
Arnaud Roth, M.D.
Geneva University Hospital
arnaud.roth@hcuge.ch

Larry Rubinstein, Ph.D.
NCI Cancer Therapy Evaluation Program
rubinsteinl@ctep.nci.nih.gov

David Ryan, M.D.
Massachusetts General Hospital
dpryan@partners.org

Leonard Saltz, M.D.
Memorial Sloan-Kettering Cancer Center
saltzl@mskcc.org

Hanna Sanoff, M.D.
University of Virginia
hsanoff@virginia.edu

Daniel Sargent, Ph.D.
Mayo Clinic
sargent.daniel@mayo.edu

Deborah Schrag, M.D., M.P.H.
Dana-Farber Cancer Institute
debschrag@dfci.harvard.edu

Gary Schwartz, M.D.
Memorial Sloan-Kettering Cancer Center
schwartzg@mskcc.org

Lawrence Schwartz, M.D.
Columbia University
l schwartz@columbia.edu

Anthony Shields, M.D., Ph.D.
Karmonos Cancer Institute
shieldsa@karmanos.org

Elin Sigurdson, M.D., Ph.D.
Fox Chase Cancer Center
e_sigurdson@fccc.edu

Charles Staley, M.D.
Emory University
cstaley@emory.edu

Abdul Tawab-Amiri, Ph.D.
NCI Coordinating Center for Clinical Trials
atawab@mail.nih.gov

Sabine Tejpar, M.D., Ph.D.
University of Leuven
sabine.tejpar@uzleuven.be

Joel Tepper, M.D.
University of North Carolina
teper@med.unc.edu

Charles Thomas, Jr., M.D.
Oregon Health and Science University
thomasch@ohsu.edu

Vincenzo Valentini, M.D.
Catholic University
vvalentini@rm.unicatt.it

Eric Van Cutsem, M.D., Ph.D.
University of Leuven
eric.vancutsem@uzleuven.be

Alan Venook, M.D.
University of California, San Francisco
venook@cc.ucsf.edu

Te Vuong, M.D.
McGill University
tvuong@jgh.mchill.ca

Lawrence Wagman, M.D.
St. Joseph Hospital
lawrence.wagman@stjoe.org

Thomas Wang, M.D., Ph.D.
University of Michigan
thomaswa@umich.edu

Martin Weiser, M.D.
Memorial-Sloan Kettering Cancer Center
weiser1@mskcc.org

John J. Welch, M.D., Ph.D.
NCI Cancer Therapy Evaluation Program
jwelch@nih.gov

Christopher Willett, M.D.
Duke University Medical Center
christopher.willett@duke.edu